How big is the Europe Cell and Gene Therapy Market?

The Europe Cell and Gene Therapy Market is valued at US$ 1,105.10 Million in 2023, it is projected to reach US$ 5,334.44 Million by 2031.

What is the CAGR for Europe Cell and Gene Therapy Market by (2023 - 2031)?

As per our report Europe Cell and Gene Therapy Market, the market size is valued at US$ 1,105.10 Million in 2023, projecting it to reach US$ 5,334.44 Million by 2031. This translates to a CAGR of approximately 21.7% during the forecast period.

What segments are covered in this report?

The Europe Cell and Gene Therapy Market report typically cover these key segments- 类型（细胞疗法、基因疗法）服务（工艺开发、cGMP 制造、监管服务、生物测定服务）规模（商业化前/研发制造、商业规模制造）

What is the historic period, base year, and forecast period taken for Europe Cell and Gene Therapy Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Cell and Gene Therapy Market report: 2025-2031 2023 2021-2023

Who should buy this report?

The Europe Cell and Gene Therapy Market report is valuable for diverse stakeholders, including: Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns. Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies. Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry. Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies. Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market. Essentially, anyone involved in or considering involvement in the Europe Cell and Gene Therapy Market value chain can benefit from the information contained in a comprehensive market report.

欧洲细胞和基因治疗市场（主要地区、市场参与者、规模和份额）- 预测至 2031 年

2023 年欧洲细胞和基因治疗市场价值为 11.051 亿美元，预计到 2031 年将达到 53.3444 亿美元；预计 2023 年至 2031 年的复合年增长率为 21.7%。

外包细胞和基因治疗制造迅速普及推动欧洲细胞和基因治疗市场

细胞和基因治疗制造是一个复杂的过程，因此正确执行和监控操作至关重要。细胞和基因治疗制造商拥有了解生物和过程工程的合格人员数量有限。此外，对于经验丰富的团队来说，使用手动和开放式制造方法管理进入首次临床试验的尝试以及构建更适合商业化的流程可能具有挑战性。因此，这些制造商选择与合同开发和制造组织 (CDMO) 合作，以加速其临床研究和商业化进程。 CDMO以合同方式为细胞和基因治疗公司提供产品开发、生产、临床试验和商业化服务。与CDMO合作，细胞和基因治疗制造商能够实现产品可扩展性、加快上市速度、无需额外成本即可获得技术专长，并提高成本效益。事实证明，将细胞和基因治疗生产外包给CDMO对制造商而言具有成本效益。他们能够利用CDMO先进的技术基础设施和专业知识。CDMO采用经过规划的、经过验证的流程来生产细胞和基因治疗产品。因此，越来越多的制造商倾向于将不断发展的细胞和基因治疗生产外包给CDMO，这推动了欧洲细胞和基因治疗市场的增长。

欧洲细胞和基因治疗市场概览

由于对生产能力建设的投资、政府的大力支持以及对该地区市场的参与等因素，预计德国的细胞和基因治疗市场在预测期内将出现显著增长。此外，顶级竞争企业的存在也将在预测期内促进该地区市场的增长。德国拥有强大的制药业，尤其注重研发。德国有 660 家生物技术公司，雇佣了 5 万名员工。其中，660 家公司专注于细胞和基因治疗 (CGT)。根据 NecstGen 的报告，2023 年有超过 29 项评估 CAR 修饰免疫细胞的活跃临床试验正在进行中，大部分生产涉及 CAR-T 细胞。此外，到目前为止，德国已经在基因治疗领域进行了 50 多项临床研究。德国 CGT 公司的创新工作主要集中在地方或国家层面，缺乏国际影响力。

欧洲细胞和基因治疗市场收入及预测至 2031 年（百万美元）

欧洲细胞和基因治疗市场细分

欧洲细胞和基因治疗市场分为类型、服务、规模、最终用户和国家。

根据类型，欧洲细胞和基因治疗市场分为细胞治疗和基因治疗。 2023 年，细胞治疗领域占有更大的市场份额。此外，细胞治疗领域又细分为同种异体、自体、病毒载体。此外，基因治疗领域又分为非病毒载体和病毒载体。

在服务方面，欧洲细胞和基因治疗市场分为工艺开发、cGMP 制造、监管服务和生物测定服务。2023 年，工艺开发领域占有最大的市场份额。

按规模划分，欧洲细胞和基因治疗市场分为商业化前/研发制造和商业规模制造。商业化前/研发制造领域在 2023 年占有更大的市场份额。

根据最终用户，欧洲细胞和基因治疗市场细分为合同研究组织、制药和生物制药公司以及学术和研究机构。 2023 年，制药和生物制药公司占据了最大的市场份额。

按国家/地区划分，欧洲细胞和基因治疗市场分为英国、德国、法国、意大利、西班牙和欧洲其他地区。2023 年，德国占据了欧洲细胞和基因治疗市场的主导地位。

Catalent Inc、Cell and Gene Therapy Catapult、Charles River Laboratories International Inc、F. Hoffmann-La Roche Ltd、FUJIFILM Holdings Corp、Lonza Group AG、乐天公司、默克集团、Takara Bio Inc、赛默飞世尔科技公司和药明康德股份有限公司是欧洲细胞和基因治疗市场的一些领先公司。

Europe Cell and Gene Therapy Strategic Insights

Strategic insights for Europe Cell and Gene Therapy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-cell-and-gene-therapy-market-strategic-framework.webp

Get more information on this report

Europe Cell and Gene Therapy Report Scope

Report Attribute	Details
Market size in 2023	US$ 1,105.10 Million
Market Size by 2031	US$ 5,334.44 Million
Global CAGR (2023 - 2031)	21.7%
Historical Data	2025-2031
Forecast period	2021-2023
Segments Covered	By 类型（细胞疗法、基因疗法） By 服务（工艺开发、cGMP 制造、监管服务、生物测定服务） By 规模（商业化前/研发制造、商业规模制造） By 服务提供商（CDMO、CMO）
Regions and Countries Covered	欧洲（英国、德国、法国、意大利、西班牙、欧洲其他地区）欧洲（英国、德国、法国、意大利、西班牙、欧洲其他地区）
Market leaders and key company profiles	Catalent Inc Cell and Gene Therapy Catapult Charles River Laboratories International Inc F. Hoffmann-La Roche Ltd FUJIFILM Holdings Corp Lonza Group AG Lotte Corp Merck KGaA Takara Bio Inc Thermo Fisher Scientific Inc.

Get more information on this report

Europe Cell and Gene Therapy Regional Insights

The regional scope of Europe Cell and Gene Therapy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.